2011-17年中国实验室诊断的严重发热伴血小板减少综合征的流行病学与临床特征:一项前瞻性观察性研究
该前瞻性观察性研究纳入2011年4月1日至2017年10月31日在中国河南省信阳市解放军医院收治的2096例实验室确诊的严重发热伴血小板减少综合征(SFTS)患者,病死率为16.2%(95%CI 14.6-17.8)。男性、高龄、入院延迟、腹泻或呼吸困难、出血体征及神经系统症状与死亡风险升高相关。基于年龄、神经系统症状及多项实验室指标构建的临床评分模型在症状出现6天内评估的患者中,总分大于8分为预测死亡风险的最佳阈值(AUC 0.879,95%CI 0.855-0.902)。利巴韦林治疗在病毒载量低于1×10^6拷贝/mL的患者中可降低病死率。
要点
- SFTS病死率为16.2%(95%CI 14.6-17.8),男性、高龄、入院延迟及神经系统症状等与死亡风险升高相关。
- 临床评分模型总分大于8分是症状出现6天内评估患者预测死亡风险的最佳阈值(AUC 0.879,95%CI 0.855-0.902)。
- 利巴韦林在病毒载量低于1×10^6拷贝/mL的患者中可降低病死率,应早期应用。
核心结论
- SFTS不断变化的流行病学特征和高病死率凸显了持续监测的必要性。
- 通过监测临床和实验室数据可实现对致命结局的早期预测。
- 利巴韦林应早期应用,在病毒载量达到1×10^6拷贝/mL之前效果最佳。
研究设计与样本
- 前瞻性观察性研究,纳入2011年4月1日至2017年10月31日在中国河南省信阳市解放军医院收治的2096例实验室确诊SFTS患者。
- 收集人口学、临床、实验室及治疗数据,随访至出院或停止治疗后2周内。
- 分析各变量与致命结局的关联,设计临床评分模型用于早期预测致命结局,并分析治疗对结局的影响。
主要发现
- 入院时平均年龄61.4岁(SD 12.2),女性1239例(59%),病死率16.2%(95%CI 14.6-17.8)。
- 男性未调整OR 1.45(95%CI 1.15-1.83;p=0.002),年龄每增加10岁未调整OR 1.82(95%CI 1.62-2.04;p<0.0001),入院每延迟一天未调整OR 1.18(95%CI 1.12-1.24;p<0.0001)。
- 腹泻调整OR 1.44(95%CI 1.12-1.87;p=0.005),呼吸困难调整OR 8.35(95%CI 5.97-11.69;p<0.0001),出血体征调整OR 2.79(95%CI 2.18-3.57;p<0.0001),神经系统症状调整OR 30.26(95%CI 21.39-42.81;p<0.0001)。
- 与死亡相关的实验室变量包括乳酸脱氢酶、天冬氨酸氨基转移酶、血尿素氮浓度异常及中性粒细胞百分比异常,与年龄和神经系统症状共同纳入临床评分系统。
- 在症状出现6天内评估的患者中,总分大于8分为预测死亡风险的最佳阈值(AUC 0.879,95%CI 0.855-0.902);对所有参与者,病毒血症是致命结局的强预测因子(所有p<0.0001)。
临床怎么用
- 作者认为,通过监测临床和实验室数据可实现对致命结局的早期预测。
- 作者认为,利巴韦林应早期应用,在病毒载量达到1×10^6拷贝/mL之前效果最佳。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease with an increasing case number and extensive geographical expansion, raising concerns locally and globally; however, the description of its clinical features needs to be addressed by large studies. We aimed to determine all the clinical features of SFTS in a large population of patients in an endemic area. METHODS: In this prospective observational study, data were collected on patients admitted to the People's Liberation Army Hospital in Xinyang, Henan Province, China, with laboratory-diagnosed SFTS. Demographic, clinical, laboratory, and treatment data were collected for each patient, and patients were followed up within 2 weeks after discharge or discontinuation of treatment. The association between each demographic, clinical, and laboratory variable with a fatal outcome was assessed. A clinical scoring model was designed for the early prediction of a fatal outcome, and the effect of treatment on outcome was analysed. FINDINGS: Between April 1, 2011, and Oct 31, 2017, 2096 patients with laboratory-confirmed SFTS were admitted. Mean age at admission was 61·4 years (SD 12·2) and 1239 (59%) patients were female. The case fatality rate (CFR) was 16·2% (95% CI 14·6-17·8). A higher risk was associated with being male (unadjusted odds ratio [OR] 1·45, 95% CI 1·15-1·83; p=0·002), older age (for a 10-year increase, unadjusted OR 1·82, 95% CI 1·62-2·04; p<0·0001), longer delay in admission (for every extra day taken before admission to hospital, unadjusted OR 1·18, 1·12-1·24; p<0·0001), presence of diarrhoea (adjusted OR 1·44, 1·12-1·87; p=0·005) or dyspnoea (adjusted OR 8·35, 5·97-11·69; p<0·0001), and development of haemorrhagic signs (adjusted OR 2·79, 95% CI 2·18-3·57; p<0·0001) or neurological symptoms (adjusted OR 30·26, 21·39-42·81; p<0·0001). Laboratory variables that were associated with death included abnormal concentrations of lactate dehydrogenase, aspartate aminotransferase, and blood urea nitrogen, and abnormal neutrophil percentage, which together with age and neurological symptoms were combined in the clinical scoring system. A total score of more than 8 was the optimal threshold to predict risk of death for patients who were evaluated within 6 days after symptom onset (area under the curve 0·879, 95% CI 0·855-0·902). For all participants, viraemia was a strong predictor of fatal outcome (all p<0·0001). Ribavirin therapy was effective in reducing CFR from 6·25% (15 of 240 participants) to 1·16% (two of 173 participants), but only in patients with a viral load below 1×106 copies per mL (hazard ratio 9·72, 95% CI 1·30-72·87; p=0·027). INTERPRETATION: The changing epidemiological features and high CFR of SFTS underscore the necessity of continued surveillance. Early prediction of fatal outcome can be attained by monitoring of clinical and laboratory data. Ribavirin should be applied early, with best results achieved before the viral load reaches 1 × 106 copies per mL. FUNDING: National Natural Science Foundation of China.
引用
- Li H, Lu QB, Xing B, et al. Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia syndrome in China, 2011-17: a prospective observational study. Lancet Infect Dis. 2018. PMID: 30054190. doi:10.1016/S1473-3099(18)30293-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。